Inovio Pharmaceuticals (GBM) Stock Statistics & Valuation Metrics

Inovio Pharmaceuticals has a market cap or net worth of CHF107.41M. The enterprise value is CHF61.11.

Inovio Pharmaceuticals has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Inovio Pharmaceuticals’s return on equity (ROE) is -3.53 and return on invested capital (ROIC) is -259.45%.

The current PE Ratio of Inovio Pharmaceuticals is ―. Inovio Pharmaceuticals’s PEG ratio is 0.02.

In the last 12 months, Inovio Pharmaceuticals had revenue of 65.34K and earned -84.95M in profits. Earnings per share was -1.81.

In the last 12 months, operating cash flow was -80.58M and capital expenditures -195.40K, giving a free cash flow of -80.78M billion.

Inovio Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Inovio Pharmaceuticals upcoming earnings date is Nov 10, 2026, TBA (Confirmed).

Inovio Pharmaceuticals as a current ratio of 1.40, with Debt / Equity ratio of 183.07%

In the past 12 months, Inovio Pharmaceuticals has paid 0.00 in taxes.

Inovio Pharmaceuticals EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -0.52.

Inovio Pharmaceuticals has CHF36.67M in cash and marketable securities with CHF8.00M in debt, giving a net cash position of CHF28.67M billion.

Gross margin is 0.00%, with operating margin of -132871.32%, and net profit margin of -130000.00%.

The average price target for Inovio Pharmaceuticals is CHF2.53, which is 11.43% higher than the current price. The consensus rating is Moderate Buy